ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Pioglitazone

Also written as “pioglitazone”, “Pioglitazone 30 mg” and “Pioglitazone and azilsartan”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus · Alzheimer Disease · Fatty Liver · Peripheral Arterial Disease, led by 10 companies.

Drug pagePioglitazone: every studyMany companies study it; this page follows only the 52 they lead. All 336 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jun 27, 200752 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takedaits history only330 open or runningphase 4since Jun 27, 2007Sep 9, 2005none ahead
Boryung Pharmaceuticalits history only42 open or runningphase 3since May 9, 2021May 9, 2021none ahead
Merck40 open or runningphase 3since Jul 22, 2008Aug 2, 2007none ahead
GlaxoSmithKlineits history only30 open or runningphase 4since Apr 2, 2009Dec 22, 2005none ahead
Hoffmann-La Rocheits history only20 open or runningphase 4since Oct 16, 2007Oct 16, 2007none ahead
Viatrisits history only20 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
Dr. Muhammad Abdulghaniits history only10 open or runningno phasesince Aug 16, 2016Aug 16, 2016none ahead
Getz Pharmaits history only10 open or runningphase 4since Jul 19, 2021Jul 19, 2021none ahead
Medtronicits history only10 open or runningearly phase 1since Jul 21, 2008Jul 21, 2008none ahead
Strekinits history only10 open or runningphase 3since Nov 1, 2017Nov 1, 2017none ahead

Also a collaborator on its studies: Parexel, Zinfandel Pharmaceuticals, Eli Lilly and Takeda Pharmaceuticals North America.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Merck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 2, 2007First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT00511108 · 211 enrolled
  2. Jul 22, 2008Phase 3 study in Diabetes Mellitus, Type 2NCT00722371 · 1,615 enrolled
  3. Apr 30, 2010Phase 1 study in OverweightNCT01115712 · 35 enrolled
  4. Sep 7, 2011Phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT01431521 · 31 enrolled

TargetBeta

PPARG →read by rule
“Peroxisome proliferator-activated receptor gamma agonist”ChEMBL 37, by rule

Other programs on PPARG

ProgramCompanyFurthest phaseStudies
saroglitazarruleZydus Lifesciencesphase 419
chiglitazarruleChipscreen Biosciencesphase 39
lanifibranorinventiva-pharmaphase 36
T3D-959rulet3d-therapeutics-incphase 33

Studies

All 4 Merck leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01431521Non-alcoholic Fatty Liver Disease1CompletedSep 18, 201231
NCT01115712Overweight1CompletedSep 201035
NCT00722371Diabetes Mellitus, Type 23CompletedOct 26, 20101,615
NCT00511108Diabetes Mellitus, Type 21CompletedFeb 24, 2009211

How it is read

Names in the registry

  • “Pioglitazone”, 33 entries
  • “pioglitazone”, 5 entries
  • “Pioglitazone 30 mg”, 4 entries
  • “Pioglitazone and azilsartan”, 4 entries
  • “TAK-379”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.